Angiosarcoma of Skin Clinical Trial
Official title:
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
Oraxol will be administered once daily for 3 consecutive days every week during the Treatment Period from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; Oraxol may be administered from Week 26 onwards. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03921073 -
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
|
Phase 2 |